SkinInjections

Re2O

Re2O is a donor-derived injectable skin booster. A small published trial reports early improvements with a Re2O-containing mixture, but does not establish broad benefit, durable results or long-term safety.

On this page

Overview

AI-generated close-up portrait of an adult East Asian woman in a bright consultation setting.
AI-generated editorial illustration; not a patient result

What it is

Re2O (리투오) is a skin booster made from human acellular dermal matrix: donated skin with its cells removed, leaving supporting material [3]. The publication names Elravie Re2O [5]. Reberry clinic describes placing it in the deeper skin layer [1]. Confirm the exact product rather than relying on the general term “skin booster”.

Trade reports link L&C Bio to the product and Humedics to a doctors’ advisory panel [2] [3].

What it involves

Clinics describe injections at multiple points [1]. A published study plan is not a universal treatment standard. The sources reviewed do not establish a standard suitable for every patient; the advisory-panel report describes plans for usage guidance [2].

Ask what else the proposed preparation contains. A clinic’s formulation may differ from a study preparation.

Reasons to discuss it with a clinician and limits

The 2026 randomized, double-blinded, split-face trial followed 20 participants for 20 weeks. A mixture containing Re2O and hyaluronic acid (HA) outperformed HA alone on measures including density, hydration and wrinkles, and on appearance ratings [5]. These findings cannot be assigned to pure Re2O.

Small size, short follow-up and incomplete correction for multiple comparisons limit confidence. Laboratory and animal findings are separate from human outcomes. L&C Bio supplied products; an author advised on development [5].

Skin texture or fine lines can have different causes. Discuss whether the available evidence fits your concern and what better-studied alternatives might offer.

Risks and considerations

The trial reported transient redness and slight swelling, with no serious adverse events. It cannot exclude rare or delayed harm [5].

The reviewed sources do not establish reliable frequencies for infection, allergic reactions or persistent lumps. Discuss these possibilities and how the clinic would assess them. Donor origin makes sourcing and traceability relevant consultation questions; company statements are not independent verification [3].

Recovery and follow-up

Reberry says injection bumps and marks usually settle within days, with individual variation [1]. This is clinic marketing, not a guaranteed recovery time.

Agree on follow-up and a contact for swelling, redness, lumps or other unexpected changes, including after travel. Ask what would require prompt medical assessment.

Questions to ask

  • Can I see the exact product, packaging and lot information?
  • How is donor tissue sourced and traced?
  • Does your preparation contain HA or other ingredients, and how does it compare with the published study?
  • What benefit is realistic for my skin, and what remains uncertain?
  • What side effects have you seen, and how are persistent reactions managed?
  • What follow-up and alternatives do you recommend?

Educational information. AI editorial and source checking are not clinical review. Checked 16 Nov 2026.

Category
Skin
General estimate
Not availableNo reviewed estimate exists. Clinic prices, when published, appear on each clinic profile.

Doctors who list re2o

No doctors documented for this procedure yet.

A doctor appears here only when their scope is documented for this procedure at an exact clinic location.

Clinics that list re2o

Offering evidence from each clinic’s own website. Availability and suitability need confirmation with the clinic.

No clinics list it yet.

Sources

Clinical references

  1. 리투오 스킨부스터 성분과 엠보/자국 회복 완전정리 가이드 · Reberry clinic · Checked 16 Nov 2026
  2. 휴메딕스, '리투오' 자문단 출범…임상 활용 기준 만든다 · Dailypharm · Checked 16 Nov 2026
  3. 엘앤씨바이오, 스킨부스터 '사체 피부' 논란 반박 · Dailypharm · Checked 16 Nov 2026
  4. Efficacy and Safety of a Particulated Human Acellular Dermal Matrix Skin Booster: A Randomized, Split-Face, Double-blinded, Prospective Clinical Trial (NCT07155278) · ClinicalTrials.gov (U.S. National Library of Medicine) · Checked 16 Nov 2026
  5. Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study · International Journal of Molecular Sciences (MDPI) · Checked 16 Nov 2026
Catalogue source
Source

This page is for research. It is not medical advice and is not a recommendation. Whether a treatment suits you, its risks and its cost need an individual consultation with a licensed doctor.

Online correction reports are not open yet.